Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,500JPY
10:29pm EDT
Change (% chg)

¥-4 (-0.27%)
Prev Close
¥1,504
Open
¥1,507
Day's High
¥1,510
Day's Low
¥1,495
Volume
2,956,100
Avg. Vol
7,851,581
52-wk High
¥1,779
52-wk Low
¥1,358

Select another date:

Tue, Mar 21 2017

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

BRIEF-Lupin's unit Kyowa and Astellas enter into agreement

* Says Astellas and Lupin s subsidiary Kyowa enter into an agreement

BRIEF-Astellas says to buy back up to 1.43 pct of own shares worth 50 bln yen

* to buy back up to 1.43 percent of own shares worth 50 billion yen Further company coverage:

BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan

* Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

BRIEF-Astellas to acquire Ganymed Pharmaceuticals 422 mln euros

* Atellas will pay eur 422 million to acquire 100% of equity in Gnymed

BRIEF-Astellas to buy Ganymed Pharmaceuticals for 422 mln euros

* Astellas says to buy Ganymed Pharmaceuticals for EUR 422 million ($460 million)

BRIEF-Astellas Pharma Inc's operating profit likely rose roughly 20% on the year for April-September half - Nikkei

* Astellas Pharma Inc's operating profit likely rose roughly 20% on the year to 160 billion yen ($1.54 billion) or so for April-September half - Nikkei

Select another date:

More From Around the Web